Justia Patents Opinion Summaries

Salazar’s patent describes technology for wireless and wired communications, including command, control, and sensing for two-way communication of sound, voice, and data “with any appliance and/or apparatus capable of transmitting and/or receiving compatible sound, voice, and data signals.” ’The patent expired in 2015. In a subsequent suit, a jury found HTC did not infringe the patent but did not decide whether the patent was valid. Salazar later sued AT&T, asserting the patent against the same products he previously challenged. HTC intervened.At claim construction, the court held that the claims require one microprocessor that is capable of performing the "recited ‘generating,’ ‘creating,’ ‘retrieving,’ and ‘generating’ functions,” explaining that the claim term provided certain functions that the “said microprocessor” must be “necessarily configured to perform as well as the structural relationship between ‘said microprocessor’ and other structural elements.” The court denied AT&T’s motion for summary judgment, based on claim preclusion and Supreme Court precedent, which prevents harassment of customers of an adjudged noninfringer. The jury found that the accused products did not infringe and that the patent was not invalid. The Federal Circuit affirmed the judgment of noninfringement, agreeing with the claim construction, did not reach AT&T’s preclusion arguments, and held that AT&T waived its challenge concerning anticipation. View "Salazar v. AT&T Mobility LLC" on Justia Law

Ironburg sued Valve for infringing its patent, entitled “Controller for Video Game Console.” In 2021, after much pretrial litigation and a change of venue, a trial was held, with each juror attending remotely through videoconferencing technology. The parties and the court agreed that each juror should have the accused product in hand. The device was mailed to each juror. Before trial, the court rejected invalidity challenges based on the purported indefiniteness of several claim terms and held that Valve was estopped from pressing its prior-art-based invalidity defenses as a consequence of Valve’s partially instituted inter partes review. The jury returned a verdict of willful infringement and assessed damages ($4 million). The court denied Ironburg’s motion to enhance damages.The Federal Circuit affirmed that the terms “elongate member” and “extends substantially the full distance between the top edge and the bottom edge” are not indefinite; the claims are infringed; the infringement was willful; damages will not be enhanced; and Valve is estopped from litigating the prior-art grounds on which IPR was requested but not instituted. The court vacated the holding that Valve was estopped from litigating its later-discovered invalidity grounds; the court erred in placing the burden on Valve concerning whether a skilled searcher conducting a diligent search reasonably would have been expected to discover certain grounds for invalidating claims. View "Ironburg Inventions Ltd. v. Valve Corp." on Justia Law

Reynolds filed a complaint at the International Trade Commission alleging that Philip Morris violated Section 337 of the Tariff Act, 19 U.S.C. 1337, through the importation and sale of tobacco products (the IQOS line of electronic nicotine delivery system products) that infringed certain claims of the 123 and 915 patents. The patents are directed to electrically powered “smoking articles” that heat tobacco instead of burning it, providing an inhalable substance in vapor or aerosol form. After an investigation, the Commission barred Philip Morris and its affiliates from importing products infringing the asserted patents.The Federal Circuit affirmed. The Commission satisfied its Section 337 duty to “consult with” the Department of Health and Human Services and asked interested government agencies, including the FDA, to provide written submissions on the public interest factor. The Commission provided a sufficient basis for the issuance of an exclusion order. Philip Morris’s argument that Reynolds’ products that had not received FDA authorization are precluded from consideration by Section 337 for purposes of its domestic industry requirement has no merit. The court also upheld findings of non-obviousness and infringement concerning the patents. View "Philip Morris Products S.A. v. International Trade Commission" on Justia Law

The 853 patent relates to universal remotes, specifically to a universal control engine that facilitates communication between a controlling device (i.e., a remote) and intended target appliances (e.g., a TV, a DVD player, a sound system, etc.). Although the specification of the patent acknowledges that universal remotes were known at the time of the invention, it states that the proliferation of new communication methods raises the potential for “confusion, misoperation, or other problems,” particularly because the preferred communication method for transmitting commands “may vary by both appliance and by the function to be performed.”. The 853 patent’s purported invention is the ability to reliably use different communication methods that enable a single remote control to provide commands to a variety of target appliances, according to the optimal method of communication for each target appliance and command.The Patent Trial and Appeal Board held that the patent’s claims had not been proven unpatentable as obvious. The Federal Circuit affirmed. The Board thoroughly considered the evidence of record and found that the skilled artisan would not have understood the prior patent’s listing of remote command codes to correspond to the claim limitation at issue. The Board’s finding in this close factual dispute is supported by substantial evidence. View "Roku, Inc. v. Universal Electronics, Inc." on Justia Law

AlterWAN sued Amazon for infringement of two patents concerning improvements to implementing wide area networks (WANs) over the Internet. The patents share a common specification that describes two core problems with WANs: latency (delay) due to uncontrolled “hops” from one node to another while the data packet is en route to its destination and the lack of security for data transmitted over the Internet. The patents purport to address those problems with a “private tunnel” that provides “preplanned high bandwidth, low hop-count routing paths between pairs of customer sites.” The parties disputed claim construction of the terms “non-blocking bandwidth” and “cooperating service provider.”The district court agreed with Amazon’s constructions: “bandwidth that will always be available and will always be sufficient,” even if the Internet is down, and changed its construction of “cooperating service provider” to be a “service provider that agrees to provide non-blocking bandwidth.” The Federal Circuit vacated a stipulated judgment of non-infringement that provided that Amazon does not infringe under the court’s constructions of the two terms. Under the circumstances of this case, the stipulation does not provide sufficient detail to the resolution of the claim construction issues presented on appeal. View "AlterWAN, Inc. v. Amazon.com, Inc." on Justia Law

Plaintiffs, Apple and four other companies, have repeatedly been sued for patent infringement and thereafter petitioned the Patent and Trademark Office (PTO) to institute inter partes reviews (IPRs), under 35 U.S.C. 311–319, with unpatentability challenges to patent claims that were asserted against them in court. They sued the PTO under the Administrative Procedure Act (APA), 5 U.S.C. 701– 706, challenging instructions issued to the Patent Trial and Appeal Board concerning how to exercise, under delegation by the Director, the Director’s discretion whether to institute a requested IPR. Plaintiffs assert that the instructions are likely to produce too many denials.The district court dismissed the APA action, finding that the Director’s instructions were made unreviewable by 35 U.S.C. 314(d): “The determination by the Director whether to institute an inter partes review under [section 314] shall be final and nonappealable.” The Federal Circuit affirmed the unreviewability dismissal of plaintiffs’ challenges to the instructions as being contrary to the statute and arbitrary and capricious. No constitutional challenges are presented. The court reversed the unreviewability dismissal of the challenge to the instructions as having been improperly issued because they had to be, but were not, promulgated through notice-and-comment rulemaking under 5 U.S.C. 553. Apple had standing to present that challenge. View "Apple Inc. v. Vidal" on Justia Law

PACT’s 908 patent relates to multiprocessor systems and how processors in those systems access data. Multiprocessor systems typically store data in several places: a main memory, where all of a system’s data is stored, and various cache memories, where smaller pieces of that same data are stored. Cache memories are closer to the processors, allowing the processors quicker access to the data available in a given cache. A system can use multiple cache levels, where a primary cache is closer to the processer but can store less data than a further-away secondary cache. The use of multiple cache memories can pose problems for cache coherency.In seeking inter partes review (IPR), Intel asserted that the prior art taught a multiprocessor system that used the separated cache and interconnect system as described in the patent. The Patent Trial and Appeal Board determined that Intel had failed to establish obviousness in light of prior art. The Federal Circuit reversed. The Board’s finding that prior art did not teach the segment-to-segment limitation and its rejection of Intel’s “known-technique” rationale for a motivation to combine lacked substantial evidence. View "Intel Corp. v. PACT XPP Schweiz AG" on Justia Law

Gilead filed an inter partes review (IPR) petition challenging claims of the University of Minnesota’s 830 patent, directed to phosphoramidate prodrugs of nucleoside derivatives that prevent viruses from reproducing or cancerous tumors from growing. The U.S. Patent and Trademark Office Patent Trial and Appeal Board found certain claims unpatentable as anticipated by the asserted prior art.The Federal Circuit affirmed. There is no “ipsis verbis” written description disclosure sufficient to support the patent’s claims, 35 U.S.C. 112. The court referred to “a compendium of common organic chemical functional groups, yielding a laundry list disclosure of different moieties for every possible side chain or functional group. Indeed, the listings of possibilities are so long, and so interwoven, that it is quite unclear how many compounds actually fall within the described genera and subgenera.” The court found no violations of the Administrative Procedures Act and rejected the University argument that sovereign immunity barred IPR proceedings against it. View "Regents of the University of Minnesota v. Gilead Sciences, Inc." on Justia Law

Jazz holds an approved New Drug Application (NDA) for the narcolepsy drug Xyrem®, with the active ingredient, GHB, which exerts a heavily sedating effect and is prone to misuse; it is known as a date rape drug. The FDA conditioned approval of Jazz’s NDA upon the development of Risk Evaluation and Mitigation Strategies (REMS). The 963 patent relates to Jazz’s distribution system, which controls access to the drug through a central pharmacy and computer database, tracking prescriptions, patients, and prescribers. Jazz listed the 963 patent in the Orange Book as covering a method of using Xyrem. The patent’s claims expired in 2022. In 2020, Avadel submitted an NDA for the GHB-based drug FT218. Unlike Xyrem, FT218 is dosed once nightly. FT218’s REMS describe multiple pharmacies and databases for ensuring proper drug handling. Although Avadel had filed an NDA, not an Abbreviated NDA, the FDA required Avadel to file a certification that to the best of its knowledge, the 963 patent’s single-pharmacy system was invalid, unenforceable, or would not be infringed by its product.Jazz sued Avadel for infringement. Avadel sued the FDA for requiring certification; the suit was dismissed because 21 U.S.C. 355(c)(3)(D)(ii)(I) provided Avadel with a separate adequate remedy. Avadel responded to Jazz’s infringement assertions, seeking de-listing of the 963 patent. The Federal Circuit affirmed the district court order that Jazz request de-listing. The 963 patent claims a system and does not claim an approved method of use. View "Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, Inc" on Justia Law

Lite-Netics sells string lights held by magnets to a surface such as a roof edge, as the assignee of two patents entitled “Magnetic Light Fixture.” Lite-Netics competes with HBL in the market for holiday string lights. Lite-Netics brought a patent-infringement action against HBL and also sent notices, one before filing suit and one after, to its customers (stores that sell the lights), some of which were also HBL customers, informing them of allegedly infringing competitors and stating Lite-Netics’s intent to enforce its patent rights. Lite-Netics did not name such competitors in the first notice. In the second notice, it identified HBL as an allegedly infringing competitor.After the second notice, HBL filed counterclaims, including for state-law torts. The district court issued a preliminary injunction, barring Lite-Netics from suggesting that HBL is a patent infringer, that HBL copied Lite-Netics’s lights, or that HBL customers might be sued. The Federal Circuit vacated. The district court abused its discretion in issuing the preliminary injunction because the applicable speech-protective legal standards were not met. Federal patent law preempts state-law tort liability for a patentholder’s good faith conduct in communications asserting infringement and warning about potential litigation. HBL’s state-law claims can survive federal preemption only to the extent that they are based on a showing of bad faith in asserting infringement. Lite-Netics’s positions have not been shown, at this stage of the litigation, to be objectively baseless. View "Lite-Netics, LLC v. Nu Tsai Capital, LLC" on Justia Law